Participants 0 107 7
Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults.
Participants 409 451 4
adult acute nonlymphocytic leukemia (ANLL)
Participants 605 786 6
The 101 eligible cases (bestatin: 48, control: 53) were analyzed; the bestatin group achieved longer remission than the control group and a statistically significant longer survival
Participants 905 950 3
15-49 yr age group, in the 50-65 yr age group
